The DOI matches its Crossref record; 44 of the 44 references it cites were found in a registry or an index.
Blood Pressure-Lowering Effect of Nebivolol in Hypertensive Patients with Type 2 Diabetes Mellitus: The YESTONO Study
Open accessAbstract
Background Effective blood pressure (BP)-lowering therapy is regarded as the most important intervention in diabetes mellitus. Nebivolol is commonly used for the treatment of hypertension, but to date there has been no study of its use in a large population of hypertensive patients with type 2 diabetes mellitus.Methods A prospective, open-label, multicentre, post-marketing surveillance study was conducted in 2838 patients with arterial hypertension requiring intervention and concomitant type 2 diabetes, with or without other diseases. The therapeutic agent was nebivolol, either as monotherapy or as add-on therapy to other antihypertensive agents, over a minimum period of 3 months, with the primary endpoint being achievement of target BPs, that is, systolic BP < or = 140 mm Hg and diastolic BP < or = 90 mm Hg. Other endpoints were changes in metabolic parameters, effects on physical capability and tolerability during treatment. Statistical analysis was prospectively planned and conducted on an intention-to-treat basis.Results Mean (SD) BP decreased from 156 (15.3)/92 (9.4)mm Hg to 135 (11)/81 (6.6)mm Hg during the treatment period, while mean (SD) heart rate decreased from 79 (10) to 71 (7) beats/min. Strict reduction of BP was associated with improvements in most metabolic parameters, including lipid levels, glycosylated haemoglobin (HbA(1c)) and microalbuminuria. Maximum physical capability improved modestly. Most patients (85%) received nebivolol 5 mg/day.Conclusions Strict BP reduction in hypertensive patients with type 2 diabetes with or without other concomitant cardiovascular diseases is achieved with nebivolol 5 mg/day in most patients. The benefits of lowering BP with use of nebivolol are associated with improvements in most metabolic parameters and in maximum physical capability.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Furthermore, it is optimal to select a β-blocker with a concomitant vasodilatory effect (eg, carvedilol, labetalol), which will have fewer adverse metabolic effects.96–98”
From Clinical management of stable coronary artery disease in patients with type 2 diabetes mellitus: a scientific statement from the American Heart Association (2020) · cites this paper as [98]
In the citing paper
“β-Blockers that have a concomitant vasodilatory effect (eg, carvedilol, labetalol, nebivolol), however, have neutral or beneficial effects on metabolic parameters.”
From Clinical management of stable coronary artery disease in patients with type 2 diabetes mellitus: a scientific statement from the American Heart Association (2020) · cites this paper as [98]
Citations
Cites
Chobanian, A. V. (2003) · JAMA · doi:10.1001/jama.289.19.2560 · Cited by 25,386
(2013) · European Heart Journal · doi:10.1093/eurheartj/eht151 · Cited by 13,655
Stearne, M. R., Palmer, S. L., Hammersley, M. S., Franklin, S. L., Spivey, R. S., Lévy, J., Tidy, C. R., Bell, N. J., Steemson, J., Barrow, B. A., et al. (1998) · UCL Discovery (University College London) · Cited by 6,094
Mancia, G., De Backer, G., Dominiczak, A., Cifkova, R., Fagard, R., Germano, G., Grassi, G., Heagerty, A. M., Kjeldsen, S. E., Laurent, S., et al. (2007) · Journal of Hypertension · doi:10.1097/hjh.0b013e3281fc975a · Cited by 5,824
Hansson, L., Zanchetti, A., Carruthers, S. G., Dahlöf, B., Elmfeldt, D., Julius, S., Ménard, J., Rahn, K. H., Wedel, H., & Westerling, S. (1998) · The Lancet · doi:10.1016/s0140-6736(98)04311-6 · Cited by 5,728
Authors/Task Force Members:, Mancia, G., De Backer, G., Dominiczak, A., Cifkova, R., Fagard, R., Germano, G., Grassi, G., Heagerty, A. M., Kjeldsen, S. E., et al. (2006) · European Heart Journal · doi:10.1093/eurheartj/ehm236 · Cited by 2,384
Adler, A. I. (2000) · BMJ · doi:10.1136/bmj.321.7258.412 · Cited by 2,133
Turner, R. D., & Holman, R. R. (1998) · Cited by 1,974
Is Pulse Pressure Useful in Predicting Risk for Coronary Heart Disease?: The Framingham Heart Study
Franklin, S. S., Khan, S. A., Wong, N. D., Larson, M. G., & Levy, D. (1999) · Circulation · doi:10.1161/01.cir.100.4.354 · Cited by 1,759
Research works printed but not linked: 3
- Buse, 2007, Circulation, 115, 114, 10.1161/CIRCULATIONAHA.106.179294 · DOI · Paper page
- Mancia, 2007, Eur Heart J, 28, 1462
- Korotkoff, 1905, Bull Imperial Mil Med Acad, 11, 365
Cited by
2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes.
Marx, N., Federici, M., Schütt, K., Müller-Wieland, D., Ajjan, R. A., Antunes, M. J., Christodorescu, R. M., Crawford, C., Di Angelantonio, E., Eliasson, B., et al. (2023) · European Heart Journal · doi:10.1093/eurheartj/ehad192 · Cited by 1,642
Arnold, S. V., Bhatt, D. L., Barsness, G. W., Beatty, A. L., Deedwania, P. C., Inzucchi, S. E., Kosiborod, M., Leiter, L. A., Lipska, K. J., Newman, J. D., et al. (2020) · Circulation · doi:10.1161/cir.0000000000000766 · Cited by 304
Effects of β-blockers on glucose and lipid metabolism
Fonseca, V. A. (2010) · Current Medical Research and Opinion · doi:10.1185/03007990903533681 · Cited by 160
A Review of Nebivolol Pharmacology and Clinical Evidence
Fongemie, J., & Felix-Getzik, E. M. (2015) · Drugs · doi:10.1007/s40265-015-0435-5 · Cited by 150
Ram, C. V. S. (2010) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2010.08.023 · Cited by 138
Metadata
- Authors
- Schmidt, A. C., Graf, C., Brixius, K., & Scholze, J.
- Affiliations
- Charité – Universitätsmedizin Berlin (DE)
- German Sport University Cologne (DE)
- Corresponding author
- Scholze, Juergen
- Venue
- Clinical Drug Investigation
- Published
- 2007
- Volume
- 27
- Issue
- 12
- Pages
- 841-849
- ISSN
- 0114-2402 (ISSN-L)
- 1173-2563
- OpenAlex
- W1984366579
- Cited by
- 46
- References
- 44
- Citations by year
- 2026: 1 · 2025: 3 · 2024: 1 · 2023: 3 · 2022: 1 · 2021: 2 · 2020: 1 · 2019: 5 · 2018: 3 · 2017: 2 · 2016: 3 · 2015: 1 · 2014: 1 · 2013: 2 · 2012: 2
- FWCI
- 3.03
- Type
- journal article
- Language
- en
- Open access
- green
- doaj.org
- Licence
- cc-by-sa
- Locations
- Clinical Drug Investigation (publishedVersion)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Blood Pressure and Hypertension Studies
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- nebivolol, type 2 diabetes, hypertension, blood pressure reduction, beta-blockers, add-on antihypertensive therapy, glycosylated haemoglobin, microalbuminuria, serum lipids, physical abilities, heart rate reduction, post-marketing surveillance
- MeSH terms
- Nebivolol, Adrenergic beta-Antagonists, Adult, Aged, Aged, 80 and over, Albuminuria, Antihypertensive Agents, Benzopyrans, Blood Pressure, Diabetes Mellitus, Type 2, Drug Therapy, Combination, Ethanolamines, Female, Heart Rate, Glycated Hemoglobin, Humans, Hypertension, Lipids, Male, Middle Aged, Product Surveillance, Postmarketing, Prospective Studies, Treatment Outcome, Exercise Tolerance
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Blood Pressure-Lowering Effect of Nebivolol in Hypertensive Patients with Type 2 Diabetes Mellitus: The YESTONO Study. https://app.cochat.ai/papers/10.2165/00044011-200727120-00006
- The paper
- Schmidt, A. C., Graf, C., Brixius, K., & Scholze, J. (2007). Blood Pressure-Lowering Effect of Nebivolol in Hypertensive Patients with Type 2 Diabetes Mellitus: The YESTONO Study. Clinical Drug Investigation. https://doi.org/10.2165/00044011-200727120-00006
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.